Business Context and Reporting Period
Immatics N.V. filed this Form 6-K on December 13, 2024, to disclose a material change in its strategic partnerships. The filing addresses a notification received on December 12, 2024, from Bristol Myers Squibb (BMS) regarding the termination of specific collaboration agreements.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics for the reporting period. However, it discloses specific transaction values related to the terminated agreements:
- Upfront Payment Retained: $60 million received under the June 1, 2022, collaboration agreement.
- Opt-in Payment Retained: $15 million received under the April 28, 2023, opt-in agreement.
- Refund Obligation: The Company is not obligated to refund any portion of these payments.
Material Changes
BMS elected to terminate two specific agreements due to ongoing portfolio prioritization efforts:
- Terminated Agreement 1: The collaboration agreement dated June 1, 2022, between Celgene Switzerland LLC and Immatics US, Inc., relating to the development of allogeneic programs.
- Terminated Agreement 2: The opt-in agreement dated April 28, 2023, between Celgene Switzerland LLC and Immatics GmbH, relating to a target under the multi-target TCR-T strategic collaboration.
- Effective Date: Terminations are effective as of March 12, 2025.
- Continuing Relationship: The broader 2019 multi-target TCR-T strategic collaboration agreement between Immatics and BMS remains ongoing.
Outlook, Risks, and Management Commentary
Management commentary is limited to the notification of the termination and the confirmation that no refunds are required. The primary risk disclosed is the cessation of development for the specific allogeneic programs and the targeted opt-in program under the terminated agreements. The filing does not provide updated financial guidance or a detailed outlook beyond the status of the remaining 2019 collaboration.
Investor Verification Checklist
- Verify the impact of the terminated allogeneic programs on Immatics' future pipeline and revenue projections.
- Confirm the scope and status of the remaining 2019 multi-target TCR-T strategic collaboration with BMS.
- Assess whether the retained $75 million in payments ($60M + $15M) will be recognized as revenue immediately or over time under applicable accounting standards.
- Review subsequent filings for any updates on the March 12, 2025, effective termination date and potential legal or operational contingencies.